Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

An estrogen receptor-beta agonist is active in models of inflammatory and chemical-induced pain.

Authors: Leventhal, L  Brandt, MR  Cummons, TA  Piesla, MJ  Rogers, KE  Harris, HA 
Citation: Leventhal L, etal., Eur J Pharmacol. 2006 Dec 28;553(1-3):146-8. Epub 2006 Sep 26.
Pubmed: (View Article at PubMed) PMID:17056036
DOI: Full-text: DOI:10.1016/j.ejphar.2006.09.033

ERB-041 (2-(3-Fluoro-4-hydroxyphenyl)-7-vinyl-1,3 benzoxazol-5-ol) is a selective estrogen receptor-beta agonist with activity in rodent models of rheumatoid arthritis and endometriosis. Clinical trials for these diseases are underway: however, the role of estrogen receptor-beta in modulating pain associated with inflammation remains unknown. These studies demonstrate that acutely administered ERB-041 is anti-hyperalgesic in preclinical models of chemical-induced and acute inflammatory pain, thus suggesting that ERB-041 may be useful for modulating pain associated with some types of inflammation.

Annotation

Disease Annotations
Objects Annotated

Additional Information

 
RGD Object Information
RGD ID: 5508846
Created: 2011-10-25
Species: All species
Last Modified: 2011-10-25
Status: ACTIVE



NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.